🇺🇸 FDA
Patent

US 10472357

Triazolopyridine compounds and methods for the treatment of cystic fibrosis

granted A61KA61K31/4196A61K31/437

Quick answer

US patent 10472357 (Triazolopyridine compounds and methods for the treatment of cystic fibrosis) held by Flatley Discovery Lab, LLC expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Flatley Discovery Lab, LLC
Grant date
Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/4196, A61K31/437, A61K31/4439, A61K31/444